Ravi Prakash Sasankoti Mohan, Jha Rohit Kumar, Chawla Riddhi, Kupendra Sushma, Kamarthi Nagaraju, Jugade Shraddha C, Tiwari Heena Dixit
Dentist and Independent Researcher, HopeHealth Inc, South Carolina, USA.
Department of Surgical Oncology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.
J Pharm Bioallied Sci. 2024 Jul;16(Suppl 3):S2733-S2736. doi: 10.4103/jpbs.jpbs_298_24. Epub 2024 Jul 31.
The purpose of this research was to evaluate, in a tertiary care context, the effects of human papillomavirus (HPV) infection on the incidence and prognosis of oral malignancies.
At a tertiary care hospital, 100 patients who received an oral cancer diagnosis between 2020 and 2022 were the subject of a retrospective analysis. Medical records were used to gather clinicopathological data, and histopathological specimens' molecular analyses were used to ascertain the HPV infection status. To assess the variations in overall and disease-free survival between HPV-positive [HPV+] and HPV-negative [HPV-] patients, survival analysis was done.
Of the oral malignancies that tested positive for HPV, 25% were caused by strains HPV-16 and HPV-18. Patients who tested positive for HPV had unique clinicopathological characteristics, such as a decreased prevalence of lymph node involvement, nonkeratinizing histology, and younger age at diagnosis. When compared to HPV- patients, HPV+ patients had substantially better overall survival ( = 0.032) and disease-free survival ( = 0.047) according to survival analysis.
The incidence and prognosis of oral malignancies are significantly impacted by HPV infection, as demonstrated by current data. When compared to HPV- cancers, HPV+ tumors have different clinicopathological characteristics and improved survival rates. These findings have implications for therapy selection and prognostication, and they highlight the significance of HPV testing in the therapeutic management of oral malignancies. To understand the underlying molecular pathways and provide tailored therapeutics for oral malignancies that are HPV+, more research is required.
本研究旨在评估在三级医疗环境中，人乳头瘤病毒（HPV）感染对口腔恶性肿瘤发病率和预后的影响。
在一家三级医疗医院，对2020年至2022年间被诊断为口腔癌的100例患者进行回顾性分析。利用病历收集临床病理数据，并通过对组织病理学标本的分子分析确定HPV感染状态。进行生存分析以评估HPV阳性[HPV+]和HPV阴性[HPV-]患者在总生存期和无病生存期方面的差异。
在HPV检测呈阳性的口腔恶性肿瘤中，25%由HPV-16和HPV-18型毒株引起。HPV检测呈阳性的患者具有独特的临床病理特征，如淋巴结受累患病率降低、非角化组织学以及诊断时年龄较轻。根据生存分析，与HPV-患者相比，HPV+患者的总生存期（P = 0.032）和无病生存期（P = 0.047）明显更好。
现有数据表明，HPV感染对口腔恶性肿瘤的发病率和预后有显著影响。与HPV-癌症相比，HPV+肿瘤具有不同的临床病理特征且生存率更高。这些发现对治疗选择和预后评估具有重要意义，并突出了HPV检测在口腔恶性肿瘤治疗管理中的重要性。为了解潜在的分子途径并为HPV+口腔恶性肿瘤提供针对性治疗，还需要更多研究。
